Founded in 2001, Shengnuo Biotechnology is a first-class international enterprise specializing in large-scale production of peptide and amino acid drugs in China.
At present, it has a number of key technologies for large-scale production of peptides that have been listed at home and abroad, and has passed the FDA certification.
It has undertaken the key research projects of major new drug creation in the 11th five year plan, and has successively won the titles of “national high-tech enterprise”, “Sichuan enterprise technology center” and “Chengdu polypeptide drug engineering technology research center”.
Shengnuo Biotechnology mainly develops and produces API and peptide drug preparations, which are applied to autoimmune diseases,
HIV-1 infected patients, etc. in addition, the company also provides professional peptide drug R & D services, and undertakes cro of domestic and foreign peptide projects, especially innovative peptide projects/ C (d) Mo business,
now has the annual production of peptide API in the ton level or above, solid preparation more than 400 million tablets (granules), freeze-dried powder injection, small volume injection, pre filled injection, cartridge injection batch production.
The company has a whole process R & D pipeline and a whole industry chain platform for peptide APIs and preparations.
It can provide pharmaceutical research services for peptide innovative drugs and generics from process route design, to small-scale test, pilot test, process validation and quality research, as well as the whole chain customized production services for API and preparation products required for drug R & D and commercial production, covering drug discovery,
clinical application, etc Complete drug development cycle from pre bed research to clinical trials and marketing. Relying on the core technology advantages of peptide synthesis and modification, the company has gained high popularity and recognition in the field of peptide drug R & D and production.
It has successively provided pharmaceutical research and customized production services for more than 30 projects for new drug R & D enterprises and scientific research institutions, such as Suzhou Paige Bio, baaotai bio, bajiayi, etc Three peptide innovative drugs have been approved to enter the commercial stage, and seven peptide innovative drugs have entered the clinical trial stage.
As one of the few domestic companies with the ability of peptide drug research and industrial transformation, Shengnuo Biotechnology has rich technology accumulation in the field of chemical synthesis of peptides.
Through independent research and development, the company has mastered a series of core technologies for large-scale production of peptide drugs, including: long chain peptide coupling technology, large-scale production technology of monosulfide cyclic peptide, synthesis technology of multiple disulfide cyclic peptide, fragment condensation technology,
polyethylene glycol modification, fatty acid modification and other independent core technologies for peptide synthesis and modification. At present, the company has 25 invention patents (including one international patent). In addition, the company also has a large number of non patented technology, mainly drug production formula and the corresponding production process.
Thanks to the long-term technology accumulation in the peptide field, Shengnuo Biotechnology has successfully developed a number of peptide API and preparation varieties,
and has become one of the few domestic enterprises that can undertake pharmaceutical research and service of high difficulty peptide innovative drugs and customized production service of peptide products. Shengnuo Biotechnology said that in the future,
it will make use of its advanced technology research and development and large-scale production capacity to further improve its profitability and promote the industrial transformation of domestic peptide new drugs.